AstraZeneca and MSD’s Lynparza (olaparib) Receive NMPA’s Approval as 1L Maintenance Therapy for BRCA-Mutated Advanced Ovarian Cancer

 AstraZeneca and MSD’s Lynparza (olaparib) Receive NMPA’s Approval as 1L Maintenance Therapy for BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca and MSD’s Lynparza (olaparib) Receive NMPA’s Approval as 1L Maintenance Therapy for BRCA-Mutated Advanced Ovarian Cancer

Shots:

  • The approval is based on P-III SOLO-1 study assessing Lynparza (bid, 300mg) as maintenance therapy vs PBO in 391 patients in a ratio (1:1) with a deleterious or suspected deleterious germline or somatic BRCA/BRCA2 mutated ovarian cancer following 1L platinum-based CT
  • The P-III SOLO-1 study result: reduction in disease progression or death by 70%; progression-free women @3yrs. (60% vs 27%); mPFS (not reached vs 13.8 mos.); median duration of follow up (40.7 vs 41.2 mos.); safety profile is consistent with the previous studies with no detriment to QoL
  • Lynparza is a PARP inhibitor act by blocking DNA damage response in tumors harboring HRR mutation including BRCA1/BRCA2, jointly developed and commercialized by AstraZeneca and MSD and is an approved therapy for the treatment of advanced ovarian cancer and metastatic breast cancer

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: FT

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post